Compare Boston Scientific Corporation (BSX) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Vanguard Growth Index Fund ETF — how do they compare? Boston Scientific Corporation trades at $43.37 (market cap $66.37B), while Vanguard Growth Index Fund ETF trades at $87.58. The key difference: Vanguard Growth Index Fund ETF is trading nearer its 52-week high, Boston Scientific Corporation nearer its low. Which is the better fit depends on your goals.
| BSX | VUG | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Sector/Thematic |
52-Week High | $108.14 | $90.29 |
52-Week Low | $42.63 | $70.00 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
VUG trades at $86.15, down 1.43% on the day, with a neutral technical signal and bullish moving averages. Recent news highlights its low 0.03% expense ratio and 411% total return over the past decade. The ETF is heavily concentrated in technology stocks (70% of assets) and executed a 1:6 stock split in April 2026.
Outlook remains positive for long-term growth investors given strong historical performance and cost efficiency, though high tech exposure and market volatility present risks. The fund's ability to adapt to economic growth trends supports its appeal, but investors should weigh concentration risk against diversification benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
